Submit Article
Back to Journal

SM Journal of Gastroenterology & Hepatology

Medically Refractory IBD in a Patient with CVID Responsive to Tofacitinib: A Case Report

[ ISSN : 3067-977X ]

Abstract
Details

Received: 13-Aug-2024

Accepted: 21-Nov-2024

Published: 23-Nov-2024

Research Article | Volume 6 - Issue 1 | Article DOI :

Download PDF

Laura Waldron¹*, Caroline Chinchilla², Lisa McMahon³, Shipra Garg⁴, Keith Sacco⁵, Brad Pasternak²

¹Pediatrics, Phoenix Children’s Hospital, Phoenix, AZ, United States
²Gastroenterology, Phoenix Children’s Hospital, Phoenix, AZ, United States
³Pediatric Surgery, Phoenix Children’s Hospital, Phoenix, AZ, United States
?Pediatric Pathology, Phoenix Children’s Hospital, Phoenix, AZ, United States
?Pediatric Allergy & Immunology, Phoenix Children’s Hospital, Phoenix, AZ, United States

Corresponding Author:

Laura Waldron, Pediatrics, Phoenix Children’s Hospital, Phoenix, AZ, United States

Keywords

Inflammatory bowel disease; Tofacitinib; Common variable immunodeficiency; Autoimmune enteropathy; Crohn’s disease; CVID enteropathy.

Abstract

A significant obstacle to effective treatment of autoimmune enteropathy and Inflammatory Bowel Disease (IBD) in Common Variable Immunodeficiency (CVID) is that both may be refractory to guideline-directed medical management. In this case report, utilization of immunologic testing to characterize activity along JAK/STAT signaling pathways revealed increased activity. As a result, Tofacitinib was successfully initiated to block downstream JAK1/3 signaling in a patient with disease previously refractory to anti-TNF-alpha and anti Il12/23 biologics.

Citation

Waldron L, Chinchilla C, McMahon L, Garg S, Sacco K, et al. (2024) Medically Refractory IBD in a Patient with CVID Responsive to Tofacitinib: A Case Report. SM J Gastroenterol Hepatol 6: 2.